SEC Form 4Coverage since May 26, 2026
$ACAD insider trading
Over the last 12 months, Acadia Pharmaceuticals insiders reported no purchases and 4 sales totaling $1.4M across SEC Form 4 filings. 75% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1.4M 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 75% pre-arranged plans
Side
Price · $ACAD · 12Mvia TradingView
Top insiders · 12m
Kihara JamesPRINCIPAL ACCOUNTING OFFICER2× · $412K
Thompson Elizabeth H.Z.EVP, Head of Research & Dev1× · $433K
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER1× · $587K
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · O | ▼ Sale | 20,141 | $29.16 | $587K | -22.9% | plan · 3 tranches |
| Jul 30, 2026 | Thompson Elizabeth H.Z.EVP, Head of Research & Dev · O | ▼ Sale | 16,558 | $26.13 | $433K | -46.6% | plan · 2 tranches |
| Jun 26, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 11,421 | $26.08 | $298K | -46.6% | plan |
| May 26, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER · O | ▼ Sale | 5,401 | $21.18 | $114K | -18.1% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ACAD feed.